Boston Children's Hospital ranked 1 in the nation by U.S. News & World Report for sixth year in a row

ERIN TORNATORE | June 18, 2012

article image
Boston Childrens Hospital is the number one pediatric hospital in the nation for the sixth year in a row according to U.S. News & World Reports 2019-20 Best Children's Hospitals rankings. We are deeply honored to have again earned the distinction of being the nation's top-ranked children's hospital," says Boston Children's CEO Sandra L. Fenwick. "It's a tribute to the doctors, nurses, researchers and so many other staff whose exceptional work every day is improving the health and well-being of children from around the world and around the corner. Congratulations to the entire Boston Children's team.

Spotlight

Lupos Biotechnology Inc

Lupos (Canada) Biotechnology is the only private cannabis technology company licensed by Health Canada in the city of Toronto. Lupos is currently a listed Licensed Dealer, as of Oct 17th of 2018 under Cannabis Act, Lupos will be licensed for 1) Standard Processing 2) Analytical Testing 3) Research & Development.

OTHER ARTICLES

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | April 9, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | April 9, 2020

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Spotlight

Lupos Biotechnology Inc

Lupos (Canada) Biotechnology is the only private cannabis technology company licensed by Health Canada in the city of Toronto. Lupos is currently a listed Licensed Dealer, as of Oct 17th of 2018 under Cannabis Act, Lupos will be licensed for 1) Standard Processing 2) Analytical Testing 3) Research & Development.

Events